SCHEMBL1152964

SCHEMBL1152964

O=C(N[C@H](c1ccccc1)C(O)(c1ccccc1)c1ccccc1)C1(C(=O)N[C@H](c2ccccc2)C(O)(c2ccccc2)c2ccccc2)CCCCC1

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HDAC4 P56524 2/20 0.37
LMNA P02545 3/20 0.36
ALDH1A1 P00352 1/20 0.35
AKR1C1 Q04828 1/20 0.35
KCNA5 P22460 2/20 0.35
MME P08473 1/20 0.34
CNR1 P21554 1/20 0.34
CNR2 P34972 1/20 0.34
HPGD P15428 1/20 0.34
KMT2A Q03164 3/20 0.34
FAAH O00519 1/20 0.34
TRPV1 Q8NER1 1/20 0.34
KDM4E B2RXH2 3/20 0.33
MEN1 O00255 2/20 0.33
HTT P42858 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
HSD11B1 P28845 1/20 0.33
KCNH2 Q12809 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1154265 0.99 LMNA (0.37) HDAC4LMNAALDH1A1AKR1C1KCNA5
SCHEMBL1154227 0.96 LMNA (0.37) HDAC4LMNAALDH1A1AKR1C1KCNA5
SCHEMBL1153374 0.93 LMNA (0.39) LMNAALDH1A1KCNA5CNR1CNR2
SCHEMBL1153891 0.91 LMNA (0.42) LMNAALDH1A1KMT2AMEN1
SCHEMBL1154175 0.90 LMNA (0.43) LMNAALDH1A1MMEKMT2AMEN1
SCHEMBL1153416 0.88 FAAH (0.41) ALDH1A1KMT2AFAAHTRPV1MEN1
SCHEMBL1153204 0.87 LMNA (0.43) LMNAALDH1A1CNR1CNR2HPGD
SCHEMBL1153400 0.86 ALDH1A1 (0.41) ALDH1A1CNR2KMT2AFAAHTRPV1
SCHEMBL1153177 0.84 MAPK1 (0.42) HDAC4LMNAMMEHPGDKMT2A
SCHEMBL1153060 0.84 ALDH1A1 (0.41) ALDH1A1CNR2KMT2AMEN1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7943799-B2 Method for producing optically active cycloalkylidenebisoxazoline compound and intermediate thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-05-17 US disclosed
US-20110046415-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE CYCLOALKYLIDENEBISOXAZOLINE COMPOUND AND INTERMEDIATE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-02-24 US disclosed
US-7842839-B2 Method for producing optically active cycloalkylidenebisoxazoline compound and intermediate thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-11-30 US disclosed
US-20070112201-A1 Method for producing optically active cycloalkylidenebisoxazoline compound and intermediate thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2007-05-17 US disclosed
EP-1698617-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE CYCLOALKYLIDENE BISOXAZOLINE COMPOUND AND INTERMEDIATE THEREOF Sumitomo Chemical Company, Limited (JP) 2006-09-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070112201-A1 Method for producing optically active cycloalkylidenebisoxazoline compound and intermediate thereof CYP3A7, GRK7, CYP2A7 HDAC4 1906/4885LMNA 1389/4885ALDH1A1 610/4885
US-20110046415-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE CYCLOALKYLIDENEBISOXAZOLINE COMPOUND AND INTERMEDIATE THEREOF CYP3A7, GRK7, CYP2A7 HDAC4 1906/4885LMNA 1389/4885ALDH1A1 610/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.